Table 1.
SSEA-4 | CD73 | CD90 | CD105 | CD146 | ||
---|---|---|---|---|---|---|
Time in culture | Culture substrate | |||||
4 days | TCP | 29 ± 4 | 45 ± 4 | 45 ± 5 | 50 ± 4 | 24 ± 4 |
CELLstart™ | 46 ± 5 | 50 ± 7 | 49 ± 4 | 47 ± 5 | 59 ± 7 | |
BM-ECM | 64 ± 6 | 67 ± 7 | 67 ± 5 | 65 ± 6 | 68 ± 7 | |
7 days | TCP | N/A | N/A | N/A | N/A | N/A |
CELLstart™ | 45 ± 7 | 44 ± 8 | 61 ± 8 | 46 ± 9 | 65 ± 8 | |
BM-ECM | 81 ± 10 | 80 ± 6 | 81 ± 7 | 70 ± 6 | 83 ± 9 |
TCP tissue culture plastic, BM-ECM bone marrow-derived extracellular matrix, N/A not applicable
Early passage (P1) cultures of BM-MSCs were grown on TCP, BM-ECM, or CELLstart™ in SFM for 4 and 7 days. Phenotypic expression of MSC-associated markers (SSEA-4, CD73, CD90, CD105, and CD146) was assessed by using flow cytometry. The data are the percent positive cells of the total cell population expressing each marker. The experiment was performed in triplicate, and the mean ± standard deviation is shown. Each experiment was performed three times